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Abstract 
 
Type II NADH:quinone oxidoreductase (NDH-2) is a proposed drug-target of major 
pathogenic microorganisms such as Mycobacterium tuberculosis and Plasmodium 
falciparum. Many NDH-2 inhibitors have been identified, but rational drug 
development is impeded by the lack of information regarding their mode of action and 
associated inhibitor-bound NDH-2 structure. We have determined the crystal structure 
of NDH-2 complexed with a quinolone inhibitor 2-heptyl-4-hydroxyquinoline-N-oxide 
(HQNO). HQNO is nested into the slot-shaped tunnel of the Q-site, in which the 
quinone-head group is clamped by Q317 and I379 residues, and hydrogen-bonds to 
FAD. The interaction of HQNO with bacterial NDH-2 is very similar to the native 
substrate ubiquinone (UQ1) interactions in the yeast Ndi1–UQ1 complex structure, 
suggesting a conserved mechanism for quinone binding. Further, the structural 
analysis provided insight how modifications of quinolone scaffolds improve potency 
(e.g. quinolinyl pyrimidine derivatives) and suggests unexplored target space for the 
rational design of new NDH-2 inhibitors. 
 
 
Key words: NDH-2; Enzyme-inhibitor complex structure; Quinolone, Quinolinyl 
pyrimidine; Bioenergetics; Electron transport chain  
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1. Introduction 
NADH:quinone oxidoreductase is an important enzyme in the respiratory system of 
many organisms. It serves as a primary entry-point for electrons in the electron 
transport chain for generation of ATP, and is responsible for maintaining cellular 
NAD+/NADH balance. Unlike the large multi-subunit complex of the proton pumping 
type I NADH:quinone oxidoreducatase (complex I) [1] and the sodium pumping type 
NADH:quinone oxidoreducatase (NQR) [2], the type II NADH:quinone 
oxidoreducatase (NDH-2) is a single subunit monotopic membrane-protein with a 
molecular mass range of 40–70 kDa [3,4]. NDH-2 catalyses exergonic oxidation of 
NADH and quinone reduction through the co-factor FAD or FMN [5-7]. These two-half 
reactions proceed through an atypical ternary mechanism regardless of the presence 
of the other substrate [6]. Crystal structures of four NDH-2 homologues from 
Saccharomyces cerevisiae [7], Caldalkalibacillus thermarum [8], Staphylococcus 
aureus [5], and Plasmodium falciparum [9] have been reported. NDH-2 comprises 
two Rossmann folds that are responsible for binding NADH and housing the co-factor 
FAD (non-covalently), are central to NADH oxidation. These domains are followed by 
a C-terminal membrane-anchoring domain in which the quinone-binding site (Q-site) 
is localised, allowing electron transfer from the reduced FAD to the acceptor quinone 
pooled in the membrane. In contrast to a canonical nucleotide-binding domain, the 
Q-site is less conserved among NDH-2 species and structural knowledge regarding 
how the quinone-substrate binds is very limited with only the yeast Ndi1-ubiquinone 
(UQ1) complex structure available. 
 
Many organisms, including bacteria, yeast, fungi, plants, and protists, harbour ndh-2 
genes in their genomes, but their absence in mammalian genomes makes NDH-2 an 
attractive target for drug development [4]. In particular, NDH-2 is a highly regarded 
target for anti-tubercular and anti-protozoal agents [9-13]. This is supported by its 
essential function in the growth and survival of Mycobacterium tuberculosis [14,15] 
and the parasitic protozoan, P. falciparum, a causative agent of malaria [16,17]. A 
number of chemical compounds such as Iodonium derivatives [16,18], flavones 
[10,19], phenothiazines [10,20], quinolones [5,12,13,17,21-25], quinolinyl pyrimidines 
[11], nanaomycin A, and polymyxin B [25,26] have been identified as inhibitors of 
NDH-2. Among these compounds, quinolones, represented by 
2-heptyl-4-hydroxyquinoline-N-oxide (HQNO) and 
1-hydroxy-2-dodecyl-4(1H)quinolone (HDQ) (Fig. 1), are the most potent inhibitors of 
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NDH-2 in many species, including Yarrowia lipolytica [22], S. cerevisiae [21], 
Gluconobacter oxydans [25], T. gondii [24], P. falciparum [12,13], and S. aureus [5]. 
Highly potent derivatives that target NDH-2 have been developed from these 
scaffolds. For example, Lin et al. noticed that quinolones with longer carbon chains (> 
C12) conferred greater potency (a half-maximal inhibitory concentration (IC50) ~ 300 
nM) than those with shorter carbon chains (IC50 > 2000 nM), against T. gondii 
TgNDH2-I [24]. More recently a structure–activity relationship (SAR) strategy was 
employed for P. falciparum NDH-2 (PfNDH-2) inhibitor development, and many 
quinolone derivatives with low nanomolar affinity and high cellular potency were 
developed (Fig. 1) [12,13]. A similar approach was adopted for inhibitor development 
for M. tuberculosis NDH-2 (Mtb NDH-2), and the quinolone pyrimidine scaffold was 
discovered to be key feature that conferred higher potency [11]. A number of 
quinolinyl pyrimidine derivatives with low nanomolar IC50 and low micromolar 
minimum inhibitory concentrations against cell growth have been developed (Fig. 1). 
 
Although many NDH-2 inhibitors have been identified, rational drug design is 
impeded by the lack of information regarding their modes of action and the unsolved 
inhibitor-bound structure. Defining the inhibition mechanism of quinolones using 
conventional inhibition kinetics has proven difficult, and results have suggested both 
competitive and non-competitive inhibition [21,22,24,25]. Generally, inhibition kinetic 
investigations of bi-substrate enzymes are challenging, as exemplified by histone 
acetyltransferase [27,28] and aldehyde dehydrogenase [29]. One needs to define the 
catalytic mechanism before deciphering the inhibition mechanism, but defining the 
catalytic mechanism itself is very challenging because bi-substrate catalysis may 
theoretically follow multiple pathways, such as a random-order ternary complex 
mechanism, a compulsory-order ternary complex mechanism, or a ping-pong 
mechanism [27]. This is indeed the case for NDH-2, and its catalytic mechanism has 
remained unclear until recently [5,6]. In 2017, a crystal structure of the PfNDH-2 
complexed with a high-affinity quinolone, RYL-552, was determined [9]. In this 
structure, the inhibitor unexpectedly bound at the dimer interface and at another site 
distant from the substrate-binding sites. Thus, the authors suggested an allosteric 
inhibition mechanism for RYL-552. However, introducing mutations in these sites did 
not eliminate the inhibition activity of RYL-552, and its inhibition activity remained high 
with a IC50 of 122 nM. This suggests the primary target of RYL-552 might be at the 
Q-site. Here, we present the crystal structure of the NDH-2–HQNO complex at 2.8 Å 
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resolution. The NDH-2 inhibited structure reveals HQNO bound at the Q-site of NDH-2 
and its inhibition mechanism competitive against quinone substrates. Further 
structural analysis shows a molecular framework for understanding both the binding of 
physiological quinone substrates and competitive inhibitors for rational drug 
development targeting NDH-2.  
 
2. Materials and methods 
2.1. Enzyme expression and purification of NDH-2 derivatives  
Wild-type (WT) and I379E C. thermarum NDH-2 derivatives were expressed and 
purified as described previously [6,8]. 
 
2.2. NDH-2 inhibitory assay 
NADH:menadione oxidoreduction assay was performed at 37 °C in 50 mM Tris-Cl 
buffer pH8.0 containing 150 mM NaCl, 1% dimethyl sulfoxide and 1% octylglucoside 
as previously described [6]. Activity was monitored by following the absorbance 
change of NADH (340–380 nm, ε = 4.81 mM-1 cm-1). For the HQNO inhibitory assay 
final NADH and menadione (MD) substrate concentrations were fixed at 200 and 50 
μM, or at 200 and 400 μM, respectively. HQNO concentrations were varied from 0 to 
100 μM and 0 to 300 μM for WT and I379E variants respectively to determine IC50 
values. Enzyme concentrations used were typically 13.5 and 60.0 ng mL-1 for the WT, 
and I379E variants respectively. Each reaction mix was pre-incubated with MD and 
HQNO for 2 minutes and the reaction was initiated by adding NADH to the mix. The 
activity was normalised against a control sample with no HQNO present in the assay 
mix. Activity assay at each HQNO concentration was performed in triplicate. For the 
inhibitory assay using a quinolinyl pyrimidine compound final NADH and menadione 
(MD) substrate concentrations were fixed at 200 and 50 μM, respectively. Enzyme 
concentration used was typically 15.0 ng mL-1. The compound concentrations tested 
were 0, 10 and 50 μM, respectively. 
 
2.3. Crystallography of the NDH-2–HQNO complex 
Crystallisation was performed employing the hanging-drop vapour diffusion method 
at 18 °C as previously described [30]. NDH-2–HQNO co-crystallisation was carried 
out using a 0.1 M Bicine–Tris pH 8.5 buffer containing 10% (w/v) PEG 4000, 25% 
(v/v) ethylene glycol, 75 mM D, L-lysine, 4% (v/v) dimethyl sulfoxide and 1 mM 
2-heptyl-4-hydroxyquinoline-N-oxide (HQNO). Crystals were harvested on day four, 
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flash-frozen and stored in liquid nitrogen. NDH-2–HQNO co-crystal diffraction data 
were collected at the Australian Synchrotron MX2 beam-line equipped with an ADSC 
Quantum 315r detector with 30% beam attenuation, 1s exposures and 1° oscillation 
angle. Data were processed using XDS [31]. 176° of data were merged and scaled 
using Aimless in the CCP4 suite [32], Molecular replacement was performed using 
Phaser [33] with a WT model (PDB: 5WED). The structures were refined using 
PHENIX [34] with NCS restraints applied, COOT [35] was used for model building 
and PyMOL [36] to create the figures. 
 
2.4. Molecular modeling of inhibitors into quinone site in PfDNH-2 
The structures of RYL552 and Triton X100 were built in Maestro [37] and then 
prepared for docking using LigPrep [38]. The quinone binding site in chain A of the 
PfNDH2 crystal structure (PDB 5JWC) was used for docking. The crystal structure of 
NDH2 was prepared using Protein Preparation Wizard [39, 40]. RYL552 and Triton 
X100 were then modelled in to the quinone binding site using Induced Fit docking 
protocol in Schrodinger Suite [41-43]. The center of grid is defined as the centroid of 
residues 50, 77, 79, 436, 440, 441, 470, 471, 472, 473, 485, 499, 502, 503, 504, 506, 
507 and 601. The van der Waals radii of ligand and receptor atoms were scaled by a 
factor of 0.5. The 20 best poses of initial docking were kept. Residues within a 5 Å 
distance of the respective docked ligand, with the exception of residues Q437 and 
Q441, were refined. The ligands were then re-docked into the receptor using extra 
precision (XP) mode, to the top 20 newly generated protein structures if the energy 
was within 30 kcal/mol of the best-modeled pose. 
 
2.5. Accession number for the crystal structure of NDH-2–HQNO complex 
Co-ordinates and structure factors have been deposited in the Protein Data Bank with 
an accession number 6BDO. 
 
3. Results and discussion 
3.1. HQNO targets the Q-site of bacterial C. thermarum NDH-2 with high specificity 
and affinity 
NDH-2 is a membrane-bound bi-substrate enzyme that catalyses the cytoplasmic 
oxidation of NADH and reduction of quinone in the membrane. It is challenging to 
define the mode of action using conventional enzyme inhibition kinetic methods that 
rely on obtaining highly accurate rates [21,22,24,25,44]. Instead, we performed a 
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structure-guided inhibition assay using a previously validated I379E C. thermarum 
NDH-2 variant, which has significantly reduced quinone-binding affinity (KMMD 20-fold 
> wild-type), but retains maximal NADH oxidation activity [6], to evaluate if the NDH-2 
inhibitor HQNO specifically targets the Q-site of C. thermarum NDH-2. We 
determined the HQNO inhibition activity against the NDH-2 derivatives using 
menadione (MD) at excess (over ten times the KM) and low (close to the KM) 
concentrations. We expected to observe an inverse correlation between the degree 
of HQNO inhibition activity and the MD concentration if HQNO and MD directly 
competed for binding. WT NDH-2 had a IC50 value of 10.5 r 1.3 μM HQNO in the 
presence of 400 μM MD (Fig. 2A). Because excess MD was present, NDH-2 retained 
40% residual activity with 100 μM HQNO. In the presence of 50 μM MD, the IC50 
value for HQNO decreased slightly to 7.3 r 1.2 μM and near complete inhibition 
(~15% residual activity) was observed with > 50 μM HQNO (Fig. 2B). Considering 
both the nearly complete inhibition of NDH-2 activity and the IC50 of 7.3 μM in the 
presence of 50 μM MD, we expected that the HQNO binding affinity will be at least 
five times that of MD. We estimated the upper limit of the HQNO KD was 
approximately 10 μM using a previously determined KMMD value of 34 μM [6].  
 
We repeated the same inhibition experiments using a I379E mutant. No inhibition was 
observed at 100 µM HQNO in the presence of 400 μM MD suggesting I379 has a role 
in binding HQNO (Fig. 2C). At 50 μM MD, HQNO inhibition was observed with a IC50 
value of 54.3 r 1.2 μM (Fig. 2D). Notably, higher HQNO concentrations were required 
for this mutant to achieve near complete enzyme inhibition at greater than 200 μM. 
The clear inverse correlation between the MD concentration and the degree of HQNO 
inhibition activity using the I379E Q-site binding mutant suggests that MD and HQNO 
compete for binding at this mutated residue. These data are consistent with the 
observation by Sena et al. that HQNO competitively inhibits binding of a quinone 
substrate for S. aureus NDH-2 [5].  
 
3.2. NDH-2–HQNO complex structure reveals HQNO specifically bound at the Q-site  
To determine the binding of HQNO to the quinone-binding site of NDH-2, we 
co-crystallised NDH-2 with HQNO using an improved NDH-2 crystallisation platform 
[30] and determined the complex structure at 2.8 Å resolution (Table 1). The presence 
of HQNO did not affect the original crystal packing of the NDH-2 enzyme. The 
structure was solved in the P21 space group with lattice parameters that were highly 
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similar to the non-ligand bound and the NAD+-bound structures [6,8,30]. After 
molecular replacement, a distinct electron density that corresponded to the HQNO 
quinone-head group immediately appeared at the Q-site of two NDH-2 molecules 
(chains B and C) in an asymmetric unit (Fig. 3). In the two remaining chains, strong 
peaks were observed at the equivalent sites, but the electron density was slightly 
disordered. We did not observe any density that might correspond to a second 
quinone molecule reported in a yeast Ndi1 structure [7], or any other parts of the 
NDH-2 molecules despite the high concentration of HQNO (1 mM) present in the 
crystallisation buffer. HQNO molecules were confidently modelled in two chains. Here, 
we describe the chain B structure, which has lower B-factors for both the protein and 
ligands than the chain C, as a representative structure. 
 
The structure shows a HQNO molecule bound in the hydrophobic Q-site localising in 
the C-terminal membrane-anchoring domain, which comprises three anti-parallel 
β-strands and the first amphipathic helix (Fig. 4A) [8]. The quinone-head group of 
HQNO is nested into a slot-shaped quinone-binding tunnel with only a few notable 
contacts established between NDH-2 and HQNO (Fig. 4B). The HQNO aromatic 
head group is sandwiched by a hydrophobic clamp formed by the pair of Q317 and 
I379 side chains, consistent with the previous MD docking model [30]. The residue 
Q317 is present in the highly conserved AQXAXQ motif found in the NDH-2 family 
proteins [8,45]. Previously, we predicted the structural role of this motif is to hold the 
linker that separates NADH- and Q-sites exposed to the cytosol and membrane, the 
side chains of two highly conserved glutamines form tight hydrogen bonds to the 
backbone of the linker [8,30]. In addition to this structural role, we suggested that the 
Q317 residue might have a direct role for quinone-binding, given this residue is 
located immediately next to the si face of the FAD isoalloxazine [8]. The 
NDH-2–HQNO structure provides further evidence that Q317, together with I379, are 
involved in recognising the quinone (from HQNO) head group. We also noticed only 
one hydrogen bond, with a distance of 2.8 Å, is formed between a HQNO carbonyl 
oxygen and a FAD isoalloxazine N3 atom (Fig. 4C). These observations agree with 
the results of a previous in silico quinone-docking study [30]. By contrast, the HQNO 
alkyl carbon tail is exposed to the solvent and disordered. The positions of the alkyl 
tail C1 to C3 atoms are supported with weak electron density but the C4 to C7 
positions have no supporting electron density (Fig. 3). No other specific interactions, 
including a hydrogen bond contact between R382 and a ketone oxygen atom of the 
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MD quinone-head that was predicted in an earlier modelling study [30], were 
observed in the structure. Upon HQNO binding, no major structural changes were 
observed and the RMSD was 0.41 Å over 394 CD atoms compared with a non-ligand 
bound structure (PDB: 5WED). The exception was a D380 side chain carboxyl, which 
moved away from the Q-site (Fig. S1). Together with previous work that NADH 
binding does not induce large conformational changes in NDH-2 [6], this new 
complex structure confirms that ligand-binding in the two substrate-binding sites does 
not induce conformational changes in bacterial NDH-2. 
 
3.3. Comparison of NDH-2–HQNO complex with yeast Ndi1–ubiquinone (UQ1) 
complex   
We compared our NDH-2–HQNO complex structure with the yeast Ndi1–UQ1 
complex structure. Comparison of the two structures identified similar binding 
orientations of the quinone-head groups in the enzymes (Fig. 4C and D) even though 
the bacterial respiratory NDH-2 and the eukaryotic yeast inner mitochondrial NDH-2 
proteins are evolutionally distant [45], and use different quinone substrates 
(menaquinone and ubiquinone) [7,8]. A UQ1 molecule bound next to a FAD molecule 
is packed against a conserved glutamine 394 (an equivalent residue to Q317 of C. 
thermarum NDH-2). In addition, a hydrophobic side chain of M485 holds the opposite 
side of the quinone aromatic ring, although M485 is not an equivalent residue to I379 
of C. thermarum NDH-2 (L481 is equivalent). Nonetheless, the packing orientation of 
the quinone-head groups in both structures were highly comparable (Fig. 4C and D). 
Another conserved contact found in both structures was a hydrogen bond between a 
carbonyl oxygen atom of the quinone head group and a N3 atom of the FAD 
isoalloxazine ring. Although more structural evidence is needed, this conserved 
quinone-head binding in the two NDH-2 structures might indicate a conserved 
quinone-binding mechanism in NDH-2. Furthermore, it suggests a common hydride 
transfer catalytic mechanism mediated via a direct hydrogen-bonding interaction 
between FAD and quinone molecules. 
 
Our bacterial NDH-2–HQNO structure suggests the inhibition mechanism of HQNO is 
to block the quinone substrate accessing to the FAD isoalloxzine. Furthermore, 
together with IC50 results and the structural similarity in the bound quinone-head 
group orientation in the bacterial and yeast structures, the mode of HQNO inhibition 
action against bacterial NDH-2 is competitive against a quinone substrate. In contrast, 
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both competitive and non-competitive inhibition modes of AC0-10 (a HQNO derivative 
with an extended alkyl tail (C11)) were reported for the yeast Ndi1 [21]. These mixed 
inhibition modes were dependent on how the catalytic reaction was initiated by 
adding either NADH or UQ1. They could have also arisen from an endogenous UQ6 
bound in the purified Ndi1 [21] and the second UQ-binding site reported for the 
Ndi1–UQ1 structure [7]. Further experimental evidence is needed to define the HQNO 
inhibition mechanism for Ndi1. However, structurally, HQNO derivatives could inhibit 
the activity of Ndi1 by binding at the UQ-binding site (Fig. 4D). 
 
3.4. Implications of the HQNO-bound NDH-2 structure to quinolone and quinolinyl 
pyrimidine NDH-2 inhibitor 
Although a number of quinolone derivatives have been developed, the structural 
basis for understanding how modifications of quinolone scaffolds improve potency is 
lacking. Thus, we analysed the NDH-2–HQNO and the Ndi1–UQ structures to gain 
insight into the molecular basis of the potent inhibition mechanisms of these 
compounds. In the Ndi1 structure, the ubiquinone isoprenyl tail is accommodated in 
the hydrophobic groove (L444, L447, I459 and L481) of the C-terminal 
membrane-anchoring domain (Fig. 5A). In our structure, the HQNO carbon tail 
extends toward the equivalent hydrophobic groove (V350, V362, L375 and A372), 
though its tail does not quite reach it because it has a shorter carbon chain (seven 
carbons) (Fig. 5B). These observations are consistent with the finding that a long 
quinolone alkyl carbon chain is associated with higher inhibition activity against T. 
gondii TgNDH2-I [24], suggesting the longer carbon chain might be interacting with 
the hydrophobic groove of the C-terminal domain in TgNDH2-I.  
 
Highly potent inhibitors for P. falciparum PfNDH-2 and M. tuberculosis Mtb NDH-2 
have been successfully developed [11-13]. Replacing the alkyl tail of quinolone at the 
2-position with an aryl substituent and addition of a methyl group at the 3-position (Fig. 
1) led to improved potency against PfNDH-2 [12,13]. Shirude et al. started from the 
quinolone–pyrimidine scaffold and discovered addition of a phenyl group, both at the 
2-position of the quinolone ring and at pyrimidine ring (Fig. 1), improved the potency 
against Mtb NDH-2 [11]. The conserved orientation of quinone derivatives found in 
bacterial and the yeast structures might indicate how the chemical modifications 
improve the potency of these quinolone and quinolinyl pyrimidine derivatives (Fig. 1). 
Assuming the quinone moieties of quinolone and quinolinyl pyrimidine derivatives 
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bind similarly in PfNDH-2 and Mtb NDH-2, their large bisaryl and phenyl pyrimidine 
groups most likely target the hydrophobic groove in the C-terminal domain of NDH-2 
because of the restricted dihedral angle between the quinone head group and the 
large hydrophobic moieties. Next, we considered how an additional 4-fluorophenyl 
group of the quinolinyl pyrimidine derivative (Fig. 1) contributed to improved potency. 
Structurally, a 4-fluorophenyl group should be accommodated in the hydrophobic 
area immediately next to FAD (Fig. 5C and D). In the Ndi1 structure, a very shallow 
hydrophobic patch is formed with W63, P92 and A393, in which one of the UQ methyl 
ether groups is accommodated (Fig. 5C). Meanwhile, in C. thermarum NDH-2, the 
slightly deeper hydrophobic pocket is formed with Y13, T46, and A316 residues (Fig. 
5D), suggesting this part might be diverse among NDH-2 species. To accommodate a 
4-fluorophenyl group, an equivalent hydrophobic pocket in Mtb NDH-2 must be larger 
than that of C. thermarum NDH-2. Supporting this, a quinolinyl pyrimidine compound 
(Fig. 1) did not show significant inhibition activity against C. thermarum NDH-2 (Fig. 
6). The chemical modifications were focused on these two regions of the quinolone 
scaffold. To develop a new set of novel NDH-2 inhibitors, the position of the nitrogen 
oxide can be targeted by medicinal chemistry to add modifications that interact with 
the hydrophobic area extending away from the quinone-binding tunnel (Fig. 5C and 
D). As this region of NDH-2 is expected to be diverse [4,7,8,45], the developed 
inhibitors may indeed have a narrow spectrum of activity. 
 
Our analysis suggests that the primary target of the PfNDH-2 inhibitor RYL-552 is the 
Q-site, given that mutations introduced in the proposed allosteric inhibition sites did 
not eliminate the inhibition activity of RYL-552 [9]. In addition, in the crystal structure 
of the PfNDH-2–RYL-552 complex, the disordered electron density at the Q-site, in 
which Triton X-100 was modelled, was potentially from RYL-552. We tested this 
hypothesis using the computational ligand-docking simulation. We first docked a 
Triton X-100 molecule into the Q-site of PfNDH-2 as it was modelled in the crystal 
structure. We found a similar binding pose to that in the crystal structure in silico (Fig. 
7A and B), with a docking score of −6.0 kcal mol−1. This confirms binding of Triton 
X-100 in the Q-site is possible. Next, we similarly docked RYL-552, finding that it was 
comfortably accommodated in the Q-site (Fig. 7C and D) with a lower docking score 
of −9.5 kcal mol−1. This suggests RYL-552 binding is energetically preferred at the 
Q-site compared with Triton X-100 binding, and the observed disordered density in 
the Q-site might be from RYL-552. The conserved binding mode of the quinolone 
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head was again predicted in this docking model (Fig. 7C and D). The head group 
orients immediately next to a FAD isoalloxazine and is clamped by residues Q437 
and L507, and a carbonyl oxygen atom of the quinone head group hydrogen bonds to 
a N3 atom of FAD (with a distance of 2.9 Å). An additional 5-fluoro group binds in a 
hydrophobic cavity formed with side chains of W50, P79, and A436, and most likely 
improves the binding affinity. Our in silico docking experiment placed a 
methylene-linked bisaryl with a terminal trifluoromethoxy group into the hydrophobic 
groove (A483, L485, F499, V502 and V503) of the C-terminal membrane anchoring 
domain. This result supports our hypothesis that the main inhibition mechanism of the 
PfNDH-2 inhibitor RY-552 is blocking of the Q-site. Notably, the tetramethylbutyl 
phenyl group of Triton X-100 contacts the same hydrophobic groove (Fig. 7A and B). 
When crystallising membrane proteins, a highly-concentrated detergent is 
unintendedly retained in the protein sample and carried over to the crystallisation 
drops because the detergent is concentrated during the protein concentration. In fact, 
a number of Triton X-100 molecules were modelled in the PfNDH-2 structures (PDB: 
5JWA, 5JWB, and 5JWC). In addition, a number of unmodelled large disordered 
electron densities, which are potentially of the detergent, were observed. Similarly, 
many Triton X-100 have been modelled in yeast Ndi1 structures (PDB: 4G6G, 4G6H, 
4G73, and 4G74), and the authors have performed co-crystallisation in the presence 
of 0.5 mM UQ to obtain Ndi1–UQ complex structures. Therefore, highly-concentrated 
Triton X-100 and inhibitors might compete for binding at the Q-site of PfNDH-2.  
 
4. Conclusions 
In conclusion, the structural analysis of bacterial NDH-2 inhibited by HQNO provides 
molecular details of the interactions and residues involved in quinone binding. The 
interaction of HQNO with bacterial NDH-2 is very similar to the native substrate UQ 
interactions in the yeast Ndi1–UQ complex structure suggesting a conserved 
mechanism for quinone binding, and moreover, a common hydride transfer catalytic 
mechanism mediated via a direct hydrogen-bonding interaction between FAD and 
quinone molecules among NDH-2 enzymes. The NDH-2–HQNO structure provides 
insight into the molecular mechanism of inhibition for new NDH-2 inhibitors (e.g. 
quinolone and quinolinyl pyrimidine derivatives) and suggests unexplored target 
space (e.g. the hydrophobic cavity extending away from the quinone-binding tunnel) 
for the rational design of new NDH-2 inhibitors. Note that during the peer-review 
process of this article, another group reported crystal structures of Ndi1 with three 
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Q-site inhibitors (5YJW, 5YJX, and 5YJY) [46]. 
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Table legend 
Table 1. Data collection and refinement statistics for the NDH-2–HQNO complex 
crystal structure. 
 
Figure legends 
Fig. 1. Quinolone and quinolinyl pyrimidine NDH-2 inhibitors described in this study. 
1) 2-heptyl-4-hydroxyquinoline-N-oxide. 2) 1-hydroxy-2-dodecyl-4(1H)-quinolone. 3) 
Bisaryl quinolone (PfNDH-2 inhibitor) [13] 4) RY-552 (PfNDH-2 inhibitor) [9] 5) 
Quinolinyl pyrimidine (Mtb NDH-2 inhibitor) [11] Bulky bisaryl and phenyl pyrimidine 
groups are enclosed in red boxes, and a 4-fluorophenyl group is enclosed in a blue 
box.  
 
Fig. 2. Determination of 2-heptyl- 4-hydroxyquinoline- N-oxide (HQNO) IC50 for 
wild-type and I379E NDH-2 variants at two menadione (MD) concentrations. A) and 
B) HQNO inhibition curves for WT NDH-2 in the presence of 400 and 50 μM MD, 
respectively. C) and D) HQNO inhibition curves for the I379E NDH-2 mutant in the 
presence of 400 μM MD and 50 μM MD, respectively. Concentration of NADH was 
set at 200 μM for all experiments. The error bars, which represent 95% confidence 
intervals, are for triplicate activity assays at each HQNO concentration. A variable 
slope model was fitted to determine the IC50 values. In each panel, NADH:MD 
oxidoreduction activities in the absence of HQNO are used for 100% and are A) 959.3, 
B) 562.5, C) 273.4 and D) 82.4 s-1, respectively. 
 
Fig. 3. The difference electron density omit map (mFo-Fc) in blue mesh countered at 
3.0σ (A) and 2.0σ (B) covers a HQNO molecule (yellow). Packing of the Q317 side 
chain against the HQNO head group and FAD is represented as a stick model. 
 
Fig. 4. Crystal structure of the NDH-2–HQNO complex. A) An overview of the 
NDH-2–HQNO complex structure showing the location of the membrane interface 
(dashed-line), FAD (blue) and HQNO (yellow). The C-terminal membrane anchoring 
domain is coloured in pink. B) A top view of a panel A (arrowed) showing the 
quinone-binding site from the membrane side. A pair of Q317 and I379 side chains 
(white) clamp a quinone-head group of HQNO (yellow). Two conserved glutamate 
residues (Q317 and Q321) in the AQXAXQ motif holding the linker that separates the 
NADH- and quinone-binding sites (hydrogen bonds are shown with dashed lines). C) 
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A side view of panel B showing a clamped HQNO head group and a hydrogen bond 
between the O1 atom of the HQNO quinone head group and the N3 atom of FAD with 
a distance of 2.8 Å. D) The binding of the quinone head group is conserved for the 
yeast Ndi1. In the yeast Ndi1–ubiquinone (UQ1) complex structure (PDB: 4G73), a 
UQ (yellow) head group is clamped with Q394 and M485 and also forms a hydrogen 
bond with FAD (blue). 
 
Fig. 5. Comparison of the Q-sites of the yeast Ndi1–UQ complex (PDB: 4G73) and 
the bacterial NDH-2–HQNO complex structure (PDB: 6BDO). A) and B) The 
hydrophobic groove (light red) formed in the C-terminal anchoring domain of the Ndi1 
and the bacterial NDH-2, respectively. C) and D) The hydrophobic cavity (blue) near 
the FAD molecule (blue stick model) of the Ndi1 and the bacterial NDH-2, respectively. 
The UQ and HQNO molecules are shown in yellow. The hydrophobic cavities 
extending away from the quinone-binding tunnel are highlighted in green. 
 
Fig. 6. Quinolinyl pyrimidine NDH-2 inhibitor (compound 5 in Fig. 1) does not inhibit 
bacterial NDH-2. Inhibition activity of the compound 5 was tested against C. 
thermarum WT NDH-2 at 0 (black line), 10 (blue) and 50 (red) μM respectively, in the 
presence of 50 μM menadione (MD) and 200 μM NADH. Each reaction mix was 
pre-incubated with MD and the compound 5 for 2 min at 37°C and the reaction was 
initiated by addition of NADH. Average values from three technical replicates with 
error bars ± SEM (n = 3) are bar-graphed. 
 
Fig. 7. In silico docking models of the PfNDH-2–Triton X100 complex and 
PfNDH-2–RYL552 complex. A) In silico docking model of the PfNDH-2–Triton X100 
complex. FAD and Triton X-100 molecules are represented as blue and yellow stick 
models. Residues involved in the hydrophobic groove of the C-terminal membrane 
anchoring domain are also represented as stick models. B) A view of panel A rotated 
by 90° clockwise. The first amphipathic helix is omitted for clarity. C) In silico docking 
model of the PfNDH-2–RYL552 complex. FAD and RYL-552 molecules are 
represented as blue and yellow stick models. Residues involved in the hydrophobic 
groove of the C-terminal membrane anchoring domain are also represented as stick 
models. D) A view of panel C rotated by 90° clockwise. The first amphipathic helix is 
omitted for clarity. Residue labels are omitted for panels C and D as the images are 
identical to those in panels A and B. 
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Supplementary material 663 
 664 
Fig. S1. The side chain of D380 changes position (cyan to green) upon HQNO 665 
binding. The structures of wild-type NDH-2 (wheat) and the HQNO complex (white) 666 
are overlaid. 667 
Table 1. Data collection and refinement statistics for the NDH-2–HQNO complex 
crystal structure. 
Wavelength (Å) 0.954
Resolution (outer shell) (Å) 48.0-2.80 (2.89-2.80)
Space group P21
Unit cell parameters a = 72.9
b = 114.3
c = 130.1
β = 91.2
Rsym  (outer shell) 0.072 (0.932)
Rpim  (outer shell) 0.069(0.883)
Mean I/σI (outer shell) 14.5 (1.7)
Completeness (outer shell) 99.8 (100.0)
Multiplicity (outer shell) 3.6 (3.7)
Total No. of reflections 190083 (16726)
No. of unique reflections 52468 (4549)
Mean (I) half-set correlation CC(1/2) 0.998 (0.446)
Wilson B factor (Å2 ) 65.4
Refinement statistics
Resolution (outer shell) (Å) 43.3-2.80 (2.85-2.80)
Rcryst 0.227 (0.367)
Rfree 0.268 (0.406)
rmsd for bonds (Å) 0.004
rmsd for angles (deg) 0.838
rmsd for chiral volume (Å3 ) 0.03
No of protein atoms 11603
No. of water atoms 43
No. of FAD atoms 212
No. of HQNO atoms 38
Average main chain B -factor (Å2 ) 67.9
Average side chain B -factor (Ă2 ) 67.8
Average water B -factor (Å2 ) 48.1
Average FAD B -factor (Å2 ) 52.7
Average HQNO B -factor (Å2 ) 71.2
Ramachandran plot statistics (%)
Favored regions 97.0
Allowed regions 2.8
Outliers 0.2
PDB entry 6BDO  
Table
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Fig. S1. The side chain of D380 changes position (cyan to green) upon HQNO 
binding. The structures of wild-type NDH-2 (wheat) and the HQNO complex (white) 
are overlaid. 
